NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma

• NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.

Sponsor

Ionis Pharmaceuticals, Inc

---

ClinicalTrials.gov Identifier: NCT04398485

Official Title: A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients With Relapsed/Refractory Multiple Myeloma

First Posted : May 21, 2020

Click here for details on ClinicalTrials.gov

---

Drug: ION251

Frenlosirsen (Code C173725)

Anti-IRF4 Antisense Oligonucleotide ION251

Anti-IRF4 ASO ION251

Anti-IRF4 ASO IONIS-IRF4-2.5Rx

Frenlosirsen

FRENLOSIRSEN

ION 251

ION-251

ION251

IONIS-IRF4-2.5Rx

ON-935918

---

- Arizona: Mayo Clinic Arizona

- Florida: Mayo Clinic Jacksonville Florida

- Minnesota: Mayo Clinic Rochester Minnesota

- Missouri: Washington University School of Medicine Saint Louis

- North Carolina: Levine Cancer Institute Charlotte

- New York: New York Presbyterian / Weill Cornell Medical College New York

- Wisconsin: Froedtert Memorial Milwaukee

---

Locations

United States, Alabama

United States, Arizona

United States, California

United States, Florida

United States, Maryland

United States, Minnesota

United States, Missouri

United States, New York

United States, North Carolina

United States, Wisconsin